John Sununu oversaw quality and compliance functions, including FDA communications, at Boston Scientific during a period when the company faced lawsuits over pelvic mesh devices, according to The Lever. The outlet reports that women suffered what it calls life-altering harm. Sununu is now the frontrunner for the New Hampshire Republican Senate nomination. The timing matters because a corporate compliance record is becoming campaign material, not a footnote in a securities filing.
Here is the stake for anyone who has ever signed off on a product safety review: the job title does not stay inside the company. Pelvic mesh litigation against device makers produced years of jury verdicts and settlements across the industry. Boston Scientific was one of several manufacturers named in that litigation. The Lever's reporting places Sununu inside the compliance function during that stretch, which is the unit typically responsible for weighing field complaints against regulatory disclosure obligations. The article does not specify which products, lawsuits, or time frame fell under his direct authority, a gap worth watching as the race continues.
What The Lever confirms is narrow and specific: a title, a company, a category of harm, and a candidacy. What it does not confirm is any individual decision Sununu made, any document he signed, or any complaint he personally reviewed. That distinction will matter as opposition researchers and reporters dig further. A compliance title describes a scope of responsibility, not a paper trail. Readers should watch for whether follow-up reporting produces internal memos, deposition testimony, or FDA correspondence bearing his name, because that is the evidence tier that turns a title into a decision.
For product and design leaders, the mechanism here is familiar and uncomfortable. Compliance and quality roles sit at the junction where engineering risk becomes legal and regulatory exposure, and the person holding that title inherits responsibility for the gap between what a company knew and what it disclosed. Device litigation like the pelvic mesh cases shows how injury claims accumulate for years before they surface in headlines, often well after the executives involved have moved to new roles. Anyone currently signing off on safety reviews, hazard analyses, or FDA communications should treat this as a reminder that those records outlive the job.
The open question is accountability design, not individual blame. Did Boston Scientific's compliance structure give Sununu authority over specific product lines, or was his role more coordinative, managing communications rather than approving designs? The Lever's piece does not resolve that, and neither corporate structure nor campaign biography is likely to settle it quickly. What is certain is that the race now carries a corporate safety record into a political contest, and that record will be read, re-read, and litigated in public long after the original compliance meetings ended.
New Hampshire voters will decide the Senate primary with that record now part of the public file.